Inhibikase Therapeutics (IKT) FDA Approvals

Inhibikase Therapeutics logo
$1.38 -0.07 (-4.83%)
Closing price 04:00 PM Eastern
Extended Trading
$1.38 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inhibikase Therapeutics' Drug in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Inhibikase Therapeutics (IKT). Over the past two years, Inhibikase Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as IKT-001. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

IKT-001 FDA Regulatory Timeline and Events

IKT-001 is a drug developed by Inhibikase Therapeutics for the following indication: Pulmonary Arterial Hypertension. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Inhibikase Therapeutics FDA Events - Frequently Asked Questions

As of now, Inhibikase Therapeutics (IKT) has not received any FDA approvals for its therapy in the last two years.

In the past two years, Inhibikase Therapeutics (IKT) has reported FDA regulatory activity for IKT-001.

The most recent FDA-related event for Inhibikase Therapeutics occurred on July 23, 2026, involving IKT-001. The update was categorized as "Designation Grant," with the company reporting: "Inhibikase Therapeutics, Inc announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of PAH."

Currently, Inhibikase Therapeutics has one therapy (IKT-001) targeting the following condition: Pulmonary Arterial Hypertension.

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:IKT last updated on 7/23/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners